Max Hodak’s Science Corp will soon place its first brain sensor in a human subject. The device is designed to monitor and stimulate neural activity. Early tests focus on delivering electrical stimulation to damaged brain or spinal cord cells. If successful, it could open new treatment paths for neurological disorders.
The sensor is part of a broader effort to restore function in injured nervous systems. Science Corp’s team has tested the technology in animal models. Human trials are expected to begin within months. Researchers aim to confirm the device’s safety and effectiveness before wider use.
One potential application is spinal cord injury rehabilitation. Electrical stimulation could help regenerate damaged pathways. Another target is epilepsy, where the sensor might detect and suppress seizures. The company has not disclosed specific patient criteria for the first trial.
Science Corp was founded in 2022 to develop neural interface tools. Hodak, a former Neuralink executive, leads the project. The company competes with other firms in the brain-computer interface space. Its approach emphasizes minimally invasive implantation.
Regulatory approval remains a key hurdle. Science Corp must demonstrate the sensor’s reliability. Long-term effects of neural stimulation are still unknown. Success could redefine treatment for conditions like paralysis and Parkinson’s disease.
Source: techcrunch.com